More MHRA Responses on the H5 Avian Influenza Vaccine
A response from the MHRA
In our Summary of the UKHSA and MHRA information received about the H5 Avian Influenza Vaccine, we kept our readers updated with the response received and our deciphering of why and how our money is being spent.
And we explained our confusion.
On Friday, Tom received more information from a review of the FOI he had requested.
The MHRA reply is the first clear indication of what went on.
The response is quite long and contains a convoluted apology (written in strange prose) for lack of clarity in responding, which is a time-wasting factor in all of these requests.
The two screenshots contain the most essential points.
This childish sketch shows you the nuts and bolts of what the MHRA is saying: EMA and MHRA consider all three current licensed or semi-licensed avian influenza vaccines bioequivalent to Sanofi’s Aflunov, which was licensed 15 years ago.
Our sharp-eyed reader Maurice McCarthy picked up the significance of this hey presto, probably because he is following the exchange on WhatDoThe…
Keep reading with a 7-day free trial
Subscribe to Trust the Evidence to keep reading this post and get 7 days of free access to the full post archives.